News Search
|
All News Topics
>
Lung Cancer
;
Press Releases by Industry Channel
>
All Lung Cancer Press Releases
Medical Evolutions 1 Inc. Rolls Out Affordable Direct to Consumer Comprehensive Pharmacogenomic Test
Better Safer Drugs the First Time
Medical Evolutions 1 Inc. Pharmacogenomic ME TEST™ Panel offers the most comprehensive pharmacogenomic test offered in the United States.
The RIGHT dose of the RIGHT drug at the RIGHT time”
WEST PALM BEACH, FLORIDA, UNITED STATES, March 22, 2018 /EINPresswire.com/ -- Medical Evolutions 1 Inc. was established to educate the general public on becoming “empowered” in participating in their own healthcare along with their physician via the Medical Evolutions 1 Inc. Pharmacogenomic Comprehensive ME TEST™. The goal is to make the ordering and utilization of the test a simple, uncomplicated yet an effective process as well as making the test economically available to most.— General
Medical Evolutions 1 Inc. Comprehensive Pharmacogenomics’ ME TEST™ is processed by a specialized, CAP, CLIA certified Laboratory which utilizes a stringently selected set of markers that have been recommended by the FDA as being clinically informative for selecting specific medications based on an individual’s unique profile. The test results may help your doctor select the right medication for you from a list of closely related medications and may help your doctor to further adjust the dosage based on your results. Medical Evolutions 1 Inc. Comprehensive Pharmacogenomic ME TEST™ Panel offers the most comprehensive pharmacogenomic test offered in the United States and covers drug-use and multiple disease states including:
Cardiovascular
Pain
Psychiatric
Urology
Infectious Disease
Gastrointestinal
Diabetes
Rheumatology
and Many More.
Alfredo Cortes
Medical Evolutions 1 Inc.
888-788-6452
email us here
Powered by
Distribution channels:
Consumer Goods, Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry, Social Media, World & Regional
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
